Back to Top

Informing, inspiring, and advancing global innovation to support a healthy, sustainable future

For Immediate Release

Current Challenges and Next Steps in Treating Pediatric Acute Respiratory Distress Syndrome

Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com

New Rochelle, NY, July 26, 2019—A new review of Pediatric Acute Respiratory Distress Syndrome (PARDS) highlights the lack of data available for standard treatment approaches and adjunctive therapies, leading to significant variability in patient management. This comprehensive review article, which also identifies a great need for studies to generate outcomes data in pediatric patients with ARDS, is published in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text open access article on the Pediatric Allergy, Immunology, and Pulmonology website.

In “The Current State of Pediatric Acute Respiratory Distress Syndrome” coauthors Kirsten E. Orloff, MD, David A. Turner, MD, FCCM, FCCP, and Kyle J. Rehder, MD, FCCM, FCCP, Duke Children’s Hospital, Durham, NC, present the physiologic basis of PARDS and describe the unique pediatric definition of the disorder and what puts a child at risk. The authors provide a thorough discussion of the current best practice strategies, including lung protective strategies as well as adjunctive options for these critically ill children. In the section entitled “Next Steps,” they call for more high-quality data to support the effectiveness of potential treatments, studies that focus on pediatric patients with severe PARDS, and outcomes data in pediatric survivors of ARDS that would assess its effects on lung function, quality of life, and neurocognitive functioning.

“Acute respiratory distress syndrome (ARDS) presents unique challenges in the pediatric age group and carries a mortality risk of approximately 24%. While this is both lower than the mortality risk for ARDS in adults and is decreasing over time in children, it continues to be a formidable problem. Accounting for up to 10% of all pediatric ICU admissions, PARDS confronts pediatric intensivists with the difficult task of identifying early signs of acute lung injury and selecting the best possible strategies for each individual child on a regular basis. This review provides a concise overview of best practice strategies to combat acute respiratory distress syndrome in children affected by this serious and potentially deadly condition,” says Pediatric Allergy, Immunology, and Pulmonology Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, Stony Brook University School of Medicine.

 

About the Journal
Pediatric Allergy, Immunology, and Pulmonology is a quarterly, peer-reviewed journal published online with open access options and in print that synthesizes the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. Led by Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, State University of New York at Stony Brook, the Journal provides comprehensive coverage to further the understanding and optimize the treatment of some of the most common and costly chronic illnesses in children. It includes original translational, clinical, and epidemiologic research; public health, quality improvement, and case control studies; patient education research; and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Tables of content and a sample issue may be viewed on the Pediatric Allergy, Immunology, and Pulmonology website.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug DeliveryBreastfeeding Medicine, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com